Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PTGES | O14684 | 7/20 | 0.33 |
| ▸ | F2R | P25116 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.32 |
| ▸ | UGCG | Q16739 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.31 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17067337 | 0.90 | PTGES (0.33) | PTGESF2RCTSSRXFP1UGCG | |
| SCHEMBL17067318 | 0.90 | CTSS (0.34) | PTGESF2RCTSSRXFP1UGCG | |
| SCHEMBL17067285 | 0.86 | SMN1; SMN2 (0.38) | SMN1; SMN2PTGESF2RRXFP1 | |
| SCHEMBL17067330 | 0.86 | DHODH (0.34) | F2RRXFP1UGCGKCNK3KCNK9 | |
| SCHEMBL29361693 | 0.85 | MEN1 (0.39) | SMN1; SMN2PTGESRXFP1KCNK3KCNK9 | |
| SCHEMBL1766704 | 0.85 | PTGES (0.36) | SMN1; SMN2PTGESCTSSRXFP1PTGS1 | |
| SCHEMBL29733643 | 0.85 | MEN1 (0.39) | SMN1; SMN2PTGESRXFP1KCNK3KCNK9 | |
| SCHEMBL1766891 | 0.85 | MEN1 (0.39) | SMN1; SMN2PTGESRXFP1KCNK3KCNK9 | |
| SCHEMBL29427851 | 0.85 | MEN1 (0.39) | SMN1; SMN2PTGESRXFP1KCNK3KCNK9 | |
| SCHEMBL22365194 | 0.85 | TACR1 (0.39) | SMN1; SMN2PTGESCTSSRXFP1KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381174-B2 | Composition and method for exterminating animal parasite | MITSUI CHEMICALS AGRO, INC. (JP) | 2016-07-05 | — | — | US | disclosed |
| US-20150297541-A1 | COMPOSITION AND METHOD FOR EXTERMINATING ANIMAL PARASITE | MITSUI CHEMICALS AGRO, INC. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2915530-A1 | COMPOSITION FOR ANIMAL PARASITE EXTERMINATION AND METHOD FOR ANIMAL PARASITE EXTERMINATION | Mitsui Chemicals Agro, Inc. (JP) | 2015-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297541-A1 | COMPOSITION AND METHOD FOR EXTERMINATING ANIMAL PARASITE | HDHD5, H1-3, TUBA3C | SMN1; SMN2 4723/4885PTGES 4131/4885F2R 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.